Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

51.8K
Overview
51.8K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Novel Small Molecule Allosteric Inhibitor of IL-17A from a DNA-Encoded Library.

ACS medicinal chemistry letters·2025
Same author

Multiclass Synthetic Accessibility Prediction.

Journal of chemical information and modeling·2025
Same author

A Target Class Ligandability Evaluation of WD40 Repeat-Containing Proteins.

Journal of medicinal chemistry·2024
Same author

Rational Design of Macrocyclic Noncovalent Inhibitors of SARS-CoV-2 M<sup>pro</sup> from a DNA-Encoded Chemical Library Screening Hit That Demonstrate Potent Inhibition against Pan-Coronavirus Homologues and Nirmatrelvir-Resistant Variants.

Journal of medicinal chemistry·2024
Same author

Sentinel lymph node biopsy may no longer be a critical component of melanoma management.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

BAUSSS biomarker improves melanoma survival risk assessment.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024

Related Experiment Video

Updated: Feb 9, 2026

Vaccines, APCs and Memory Cells
01:51

Vaccines, APCs and Memory Cells

51.8K

Amputation for soft-tissue sarcoma.

Matthew A Clark1, J Meirion Thomas

  • 1Department of Surgery, Middlemore Hospital, Auckland, New Zealand.

The Lancet. Oncology
|June 6, 2003
PubMed
Summary
This summary is machine-generated.

Major amputation for soft-tissue sarcomas is reserved for select cases after exploring all other options. This rare procedure can offer palliation and long-term survival for carefully chosen patients.

More Related Videos

Cancer Vaccines
01:30

Cancer Vaccines

1.1K

Related Experiment Videos

Last Updated: Feb 9, 2026

Vaccines, APCs and Memory Cells
01:51

Vaccines, APCs and Memory Cells

51.8K
Cancer Vaccines
01:30

Cancer Vaccines

1.1K

Area of Science:

  • Oncology
  • Surgical Oncology
  • Orthopedic Oncology

Background:

  • Soft-tissue sarcomas are rare malignant tumors often originating in the limbs.
  • Standard treatment involves wide local excision and radiotherapy.
  • Major amputation is reserved for complex cases like proximal, large, high-grade, or recurrent tumors, or those involving major neurovascular structures.

Purpose of the Study:

  • To review the role and outcomes of major amputation in managing challenging soft-tissue sarcoma cases.
  • To emphasize the importance of multidisciplinary assessment for limb-sparing alternatives before considering amputation.

Main Methods:

  • Review of indications and outcomes for major limb amputation in soft-tissue sarcoma.
  • Discussion of alternative treatments including limb-salvage surgery, neoadjuvant therapy, and novel techniques.
  • Emphasis on referral to specialized sarcoma units for comprehensive evaluation.

Main Results:

  • Major amputations (forequarter, hindquarter) are uncommon but necessary for specific advanced soft-tissue sarcomas.
  • Outcomes are variable, but amputation can provide palliation for severe symptoms.
  • Carefully selected patients may achieve long-term disease-free survival and reasonable function.

Conclusions:

  • Major amputation should remain a viable option for carefully selected soft-tissue sarcoma patients.
  • Thorough evaluation of all limb-sparing and oncologic treatment options is crucial prior to amputation.
  • Specialized sarcoma units are essential for optimal patient management and decision-making.